Gaudium IVF Q1 PAT falls 42% YoY to Rs1.78 Cr on expansion spend; revenue up 9%
PAT -42.27% YoY · revenue +9.13% · margins compressing
₹19.38 Cr
+9.13% YoY
₹1.78 Cr
-42.27% YoY
8.66%
₹0.25
Gaudium IVF's Q1 FY27 consolidated (primary) revenue rose 9.1% YoY to Rs19.38 Cr (Rs17.76 Cr a year ago) but consolidated PAT fell 42.3% YoY to Rs1.78 Cr (Rs3.08 Cr) - profit trailing revenue by a wide margin is the defining feature of the quarter. Standalone tells a shallower version of the same story: PAT down 29.2% YoY to Rs1.66 Cr on revenue up 11.4% to Rs13.68 Cr. The roughly 13-point gap between the standalone and consolidated PAT declines is a real divergence (>3%) and readers comparing the two bases should note consolidated is the weaker number. Sequentially, both revenue (-36.2% QoQ from Rs30.35 Cr) and PAT (-78.7% QoQ from Rs8.36 Cr) look sharply weaker, but the Q4 FY26 comparator is itself a derived 'balancing figure' between the audited full year and the reviewed nine-month numbers (per the auditor's note), not an independently reported quarter - so the QoQ swing is partly a base-quality artifact, and the YoY read is the one to anchor on.
Q1 FY-2027 vs prior quarters
No year-ago quarter on record — YoY cells may be blank.
The compression sits squarely on the expense side, not revenue. Consolidated OPM nearly halved to 12.5% from 29.0% a year ago, and NPM fell to 8.7% from 17.3%, driven by sales and marketing spend that jumped 148% YoY to Rs4.04 Cr (+71% sequentially) and employee benefit expense up 25% YoY to Rs2.28 Cr - both tied to staffing and go-to-market costs for the FY27 hub rollout. Partially offsetting this, finance costs fell 24% YoY to Rs0.38 Cr after the company repaid its entire Rs18.07 Cr of outstanding borrowings during the quarter using IPO proceeds, removing what had been a meaningful cost line.
What the summary numbers don't show
Consolidated EPS (not annualised) Rs0.25 vs Rs0.50 YoY and Rs1.34 QoQ
First full quarter as a listed company (listed Feb 27, 2026) — 11th AGM scheduled September 28, 2026
The company carries no analyst consensus or brokerage coverage that a search could find - it listed only in February 2026, and no Q1 FY27 estimates or initiation reports surfaced, so vsStreet is unknown. There is likewise no formal prior guidance on record and none turned up in search; management gives no formal guidance and the only forward framing accompanies this print itself. Operationally, the quarter included commencement of a new Delhi centre (July 15) and the launch of an AI-powered diagnostics lab as the company began its planned 19-centre expansion (July 16); of the Rs50 Cr IPO allocation earmarked for new-centre capex, only Rs1.03 Cr had been deployed as of June 30, 2026, so the bulk of that investment - and its revenue contribution - is still ahead. Management's own framing, from the press release, calls the quarter 'a period of measured progress' with revenue growth 'reflecting the resilience of our mature hubs,' while explicitly describing profitability as 'consciously moderated' to fund 'clinical talent, systems and readiness' for the ten hubs planned this year - directly consistent with the margin and cost-line detail above.
W1
OPM was 12.5% this quarter vs 29.0% YoY and 40.1% in Q4 FY26 - watch whether it recovers as new hubs ramp or stays compressed through the FY27 build-out
W2
Only Rs1.03 Cr of the Rs50 Cr IPO capex allocation for new centres was deployed as of June 30, 2026 - watch drawdown pace as the 19-centre expansion, including the new Delhi centre and AI labs, executes
W3
Sales & marketing spend more than doubled YoY to Rs4.04 Cr - watch whether this level is sustained or normalizes as new centres mature
Figures converted from Rs Lakh (source statement) to Rs Cr; standalone and consolidated both tie out (PBT-tax=PAT; totalIncome=revenue+otherIncome). Q1 FY26 comparator carries an immaterial Rs0.24 lakh discontinued-operations loss (EKK Global, disposed Aug 2025) folded into the consolidated 'Profit for the Period' used for YoY. Q4 FY26 column is a derived/balancing figure (audited full year less reviewed 9M), not an independently reported quarter, per the auditor's note - QoQ swings should be read with that caveat.
Clinical excellence meets execution risk: the ₹19.4 Cr quarter that didn't keep pace
Gaudium delivered 9.1% revenue growth and a 42% profit collapse in Q1, yet management guided for 30% FY growth and margin recovery. The call exposed a widening gap: the moat is real, but the momentum is not.
₹1.8 Cr
-42.3% YoY
12.5%
vs 29% Q1 FY26 (–1,651 bps)
30% growth
needs 40%+ in Q2–Q4
The core tension
On paper, Gaudium delivered ₹19.4 Cr in revenue — a 9.1% YoY increase — and ₹1.8 Cr in PAT. But the headline masks a profit collapse: PAT fell 42% despite mid-single-digit volume growth. That inverse relationship signals one of two things: negative operating leverage or a structural margin erosion. The answer is both. EBITDA margin crashed 1,651 basis points from 29% to 12.5%, a plunge management attributes to ~₹2.95 Cr in one-time expansion costs (South Extension pre-operations, SiD/ERICA marketing, clinical talent hiring). If true, adjusted margin would be 27.6%. If not, the margin story is broken. That uncertainty — layered on top of a 30% FY growth target that requires 40%+ growth in the next three quarters after a 9% start — is why the call felt defensive.
What holds up from the call
9.1% YoY revenue growth to ₹19.4 Cr
Q1 FY26 was ₹17.8 Cr; (19.4 − 17.8) / 17.8 = 9.1% ✓
Supported
PAT moderation to ₹1.8 Cr
Q1 FY26 was ₹3.1 Cr; 1.8 / 3.1 = 58% of prior year = 42% decline
Supported (but language was 'modest moderation'; 42% is steep)
EBITDA margin 12.5% reflects expansion one-offs; adjusted ~27.6%
12.5% is actual; ₹2.95 Cr one-off claim is plausible but unverified in filings
Partially overstated (relies on unaudited one-off allocation)
30% FY27 growth target based on historical ~30% delivery
FY26 growth was 46%, FY25 was 48% — declining trend. 30% is LOWER than recent history
Overstated (describes downgrade as baseline)
South Extension hub operational and revenue-contributing
Opened July 16, 2026; Q1 ended June 30. Negligible Q1 contribution; future ramp unproven
Contradicted (timing claim overstated)
Clinical pregnancy success rate 62% first attempt at global standards
No contradictory evidence in results; metric not reported in financial statements
Unverified (plausible, but not in filed data)
What changed on this call
Margin compression accelerated: 1,651 bps drop to 12.5%. Largest single negative vs prior year.
Revenue growth decelerated sharply: FY26 was 46% YoY, Q1 FY27 is 9.1% YoY. Declining trajectory despite AI investment.
Clinical outcomes upgraded: first-attempt success rate rose to 62% (from 58% baseline), driven by SiD/ERICA AI embryology deployment. ~8% lift in early results.
Expansion roadmap confirmed: South Extension hub now live (July 16); Gurgaon and Nagpur launching within 25 days. 10-hub FY27 target on track.
No prior FY27 guidance to assess. First time management anchored 30% growth; no way to check against prior promise.
The bull and bear case
Genuine clinical and technology moats: AI embryology (SiD/ERICA) is first-mover advantage in India; 62% first-attempt success is at global benchmark.
Vast untapped TAM: 27.5M infertile couples in India, 1% IVF penetration. ART Act regulatory consolidation favors organized, scale-based players.
Disciplined, funded expansion: 10-hub capex (₹25 Cr) + Lucknow hospital (₹15 Cr) on track; IPO proceeds funded.
Reported profit declined 42% despite 9% revenue growth: negative operating leverage. Margin story relies on unverified one-off allocation.
Q1 miss contradicts 30% FY guidance: 9.1% growth in Q1 requires 40%+ in Q2–Q4 to average 30%. Steep execution bar; if Q2 disappoints, guidance withdrawn.
ART Act rollout still nascent: management acknowledged 1–2 years to full implementation. Consolidation thesis depends on enforcement; not yet reflected in competitive dynamics.
New-hub unit economics unproven in Tier 2 markets: Tier 2 hubs target 30 cycles/year (~₹60 lakhs revenue). Execution risk in unfamiliar cities where brand is unproven.
International spokes nascent: Paris, Nigeria, Sydney just launched. Ramp-up timeline and patient volume predictability unclear.
How the street is positioned
FII exodus. Foreign institutional investors fled hard: from 6.70% in Q4 FY26 to 3.02% in Q1 FY27, a 368 basis point drop. DII remained flat (2.62% → 2.22%, only 40 bps). Promoters unchanged at 71.29%. The FII exit is the market's own verdict: institutions see execution risk that the clinical moat doesn't yet offset. Domestic mutual funds are not rushing in to offset the outflow.
Valuation and technicals. The stock trades at ₹116.1, down 29% from its all-time high of ₹163.7 and down from the 52-week high but up 67.77% from the 52-week low of ₹69.2. It sits below both its 20-day and 50-day simple moving averages (SMA20 ₹133.11, SMA50 ₹124.85), signalling continued downtrend. RSI at 14.9 is technically oversold — textbook capitulation territory. But volume is decreasing, not surging, which rules out a panic flush. This is quiet disappointment, not panic selling.
Recent activity. Bulk deals in April 2026 show HRTI (an affiliate entity) buying 4.67 lakh shares at ₹112.54 and selling 5.28 lakh at ₹113.55 — a small round-trip, not a signal of insider conviction. No promoter selling near the highs to flag.
The picture is cohesive: institutions are waiting for proof that Gaudium can convert its clinical moat into earnings growth. Q1 didn't provide it. The stock's oversold technicals suggest some bounce-back is overdue, but volume tells you it's not a setup for a sustained rally — it's a reprieve until Q2 growth is announced.
Risks, ranked by how much they should concern a holder
Q1 weak start vs 30% FY guidance
High9.1% Q1 growth requires 40%+ in Q2–Q4 to average 30% FY. If Q2 soft, guidance withdrawn and stock reprices lower. Concentration of risk on hub ramp-up execution.
Negative operating leverage (profit down 42% on 9% revenue growth)
HighSignals either structural margin erosion or genuine one-off costs. If the latter doesn't reverse, adjusted margin narrative collapses and the stock is cheaper.
ART Act rollout nascent (1–2 years to full implementation)
HighConsolidation thesis depends on effective regulation. Unorganized players (70% of market) may not consolidate; they may fragment. Gaudium's advantage may not materialize as fast as priced.
New-hub execution in Tier 2 markets (brand unproven)
MediumUnit economics (30 cycles/year Tier 2, ~₹60 lakhs revenue) may not hold in unfamiliar cities. Ramp-up delay or lower-than-expected volumes would force capex recuts.
Seasonality as blanket excuse (Q1 'heat' narrative)
MediumPlausible but convenient. If H2 growth fails to accelerate, seasonality becomes a cover story for structural demand softness.
Competitive pressure from organized players entering IVF
MediumMargin erosion risk if growth slows further and larger players (Apollo, Max, Fortis) scale their IVF offerings.
The debate
What to watch next
1 · Q2 FY27 growth trajectory (Sep 2026 results)
If hub ramp-ups deliver and organic growth inflects to 20%+, the 30% FY target becomes credible. If Q2 is also in single digits, guidance is toast.
2 · Margin recovery proof (adjusted EBITDA narrative)
Q2 will show whether the one-off cost story holds or whether margins are permanently compressed. Recovery toward 25%+ by Q3–Q4 is the margin thesis; flat or lower margins mean structural headwind.
3 · New-hub ramp and utilization rates (H2 FY27)
South Extension, Gurgaon, and Nagpur will begin contributing revenue. Volume per hub and achieved margins will show whether the expansion model is scalable or whether Tier 2 unit economics are weaker than guided.
The close
Gaudium IVF has the clinical moat and TAM to become a significant health-care compounder, but Q1 FY27 is a reset, not a trough. Revenue growth collapsed to 9.1%, profit fell 42%, and EBITDA margin crashed 1,651 basis points — a pattern that management attributes to one-time expansion costs (₹~2.95 Cr) but has not yet proven to investors. The 30% FY guidance is aggressive given a 9% Q1 start and requires execution flawless in Q2–Q4.
The institutional exit (FII from 6.7% to 3%) and oversold technicals (RSI 14.9) suggest the stock is due for a bounce, but the volume decline tells you it's a reprieve, not a restart. Conviction will return only when Q2 growth inflects and margin recovery is demonstrated.
Hold the name for now. The long-term structural case (AI moat, regulatory tailwind, underpenetrated TAM) remains intact. But don't add into this quarter — wait for proof of execution in H2 FY27. The number to track from here is organic growth (not one-off-adjusted EBITDA): if it stays below 15% through Q3, the 30% FY target is illusory and the stock reprices sharply lower.
Clinical edge intact, but Q1 miss clouds aggressive 30% recovery guidance
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Q1 numbers match filed results exactly. One-off expansion narrative is plausible but unverified. No prior FY27 guidance to assess track record. Margin collapse is largest risk.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Gaudium has genuine clinical and technology moats (AI-led embryology, 62% first-attempt success, first-mover in India), and the IVF market TAM is vast and underpenetrated. However, Q1 delivered only 9.1% revenue growth and 42% PAT decline—a weak result that contradicts management's 30% FY guidance. The EBITDA margin collapsed 1,651 bps to 12.5%, attributed to one-off expansion costs (₹~2.95 Cr), but recovery is unproven. Expansion is disciplined and funded, yet new hub ramp-up in new cities carries execution risk. The ART Act regulatory tailwind is real but still nascent across states. Short-term recovery from Q1 miss is uncertain; long-term structural case is solid but not yet reflected in current delivery.
₹19.4 Cr
Revenue · +9.1% YoY₹1.8 Cr
Reported PAT · −42.27% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
9.1% YoY revenue growth to ₹19.4 Cr
Delivered result confirms ₹19.4 Cr revenue vs ₹17.8 Cr in Q1 FY26 = 9.1% growth
MET
PAT at ₹1.8 Cr with moderation on YoY basis
Delivered ₹1.8 Cr PAT vs ₹3.1 Cr prior year = 42% decline, not modest moderation
MET
Reported EBITDA margin 12.5% reflects one-off expansion costs
EBITDA margin 12.5% vs 29% prior year (1,651 bps drop). Management claims ₹~2.95 Cr in expansion one-offs would yield adjusted margin 27.6%, but unverified
Partially Overstated
30% FY27 growth target based on historical 30% delivery
FY26 growth was 46%, FY25 was 48% — declining trend. 30% is LOWER than recent history, not higher
OVERSTATED
Clinical pregnancy success rate 62% first attempt at global standards
No contradictory evidence in results; clinical metrics not reported in financial statements, claim plausible
Unverified
South Extension hub became operational and revenue contributing
Opened July 16, 2026 (after Q1 ended June 30), so minimal Q1 contribution; future impact unproven
MISS
Earnings quality
What changed since the last call
EBITDA margin compressed 1,651 bps
DowngradeQ1 FY26 margin 29% → Q1 FY27 12.5%. Driven by SiD/ERICA marketing (pan-India), pre-ops at South Extension, clinical talent hiring. No specific prior quarter guidance to compare, but absolute level is weak.
Revenue growth decelerated
DowngradeFY26 growth 46%, FY25 48%, Q1 FY27 YoY growth 9.1%. Declining trend despite AI investment and expansion. Management attributes to Q1 seasonality and center construction.
Clinical outcomes improved (stated)
UpgradeFirst-attempt success rate rose to 62% from 58% prior baseline, driven by SiD/ERICA deployment (~8% improvement claimed in early results). First-mover moat in India per IVF 2.0 certification.
Expansion roadmap confirmed live
NeutralSouth Extension hub now operational (July 16, 2026). Gurgaon and Nagpur in 10-25 days. 10-hub target for FY27 on track, but execution risk on new-market ramp-up remains.
The Q&A
Analysts pressed hard on sluggish 9% growth vs large base and prior high-30s% growth trend. Management defended via seasonality narrative and infrastructure focus, but didn't break down volume vs pricing. On margins, analysts sought reassurance of recovery to FY26 levels; management reaffirmed but offered no detailed path. ART Act implementation depth questioned; management acknowledged nascent rollout (1-2 years away). Overall, Q&A tone was respectful but skeptical—investors wanted proof of execution, not just expansion plans.
Growth deceleration — Arman, Blue Sky Fintech
PartialQ1/Q3 seasonally weak (heat, patient perceptions). Centers under construction, AI integration focus. New hubs will kick in Q2-Q4. Historical 30% YoY growth sustainable; industry CAGR 10-12%.
Hub breakeven & hospital rationale — Vileh Rai, KamayaKya Wealth
Answered3-month breakeven historically vs 6-month guidance. Lucknow hospital core IVF + women's health extension. Lucknow is UP capital (untapped market), not diverting IPO proceeds, internal accruals funded.
Competitive positioning & ART Act — Anuj Goyal, Bastion Research
PartialUSP is clinical excellence + SOP model + AI moat. ART Act enabling consolidation (30% organized → higher). Mushroom centers won't survive regs. 70% unorganized market consolidating toward leaders.
Margin recovery path — Raman KV, Sequent Investments
PartialOne-time heavy marketing push for SiD/ERICA pan-India. Strategic differentiator + clinical uplift. Expect reward rest of year. Yes, margins to recover to FY26 levels.
FY27 guidance specifics — Jyotish Nair, Moat Financial
Answered30% growth year-on-year. Sustain EBITDA and PAT. Historical 30% delivered, will replicate.
AI technology differentiation — Priyansh Miri, NGP Family Office
AnsweredFirst in India (certified by US-based IVF 2.0). SiD assesses best sperm in real-time; ERICA rates embryos via 2.5M parameters. ~8% first-attempt success lift (early results, longer data needed). Standardizes embryologist skill across network.
Guidance
FY27 revenue growth 30% year-on-year
MediumStated explicitly multiple times; based on historical ~30% track record and new hub ramp-ups. Q1 start of 9.1% means Q2-Q4 must average 40%+ to hit target—steep recovery required
EBITDA margins similar to FY26 levels by end of year
MediumFY26 margins ~29-30%. Q1 at 12.5% requires recovery to ~25-28% by Q4 to average ~20% for full FY27. Contingent on one-offs not recurring and hub ramp-ups reaching run-rate margins
FY27 capex ~₹25 Cr for 10 new IVF hubs (₹2.5 Cr per hub) + ₹15 Cr Lucknow women's hospital (funded internally, FY28-FY29 commercialization)
HighFunded via IPO proceeds (hubs) + internal accruals (Lucknow). On track per management; 1 hub live, 2 more in pipeline
Risks the call surfaced
Growth execution
HighQ1 delivered 9.1% growth; 30% FY target requires 40%+ growth in Q2-Q4. Execution on 10 new hub ramp-ups in parallel poses concentration of risk. If Q2 disappoints, guidance will be withdrawn.
Margin pressure
HighEBITDA margin collapsed 1,651 bps to 12.5%. Management attributes ₹~2.95 Cr to expansion one-offs (SiD/ERICA marketing, pre-ops, clinical hiring). If one-offs persist or competition forces price cuts, adjusted margin recovery narrative fails.
Regulatory execution
MediumART Act (2022) is in 'various stages' of implementation across states. Some have state boards and registrations; others lack bank accounts for fee transfers. Full implementation 1-2+ years away. Consolidation tailwind is contingent on effective enforcement.
Market saturation risk
MediumJanakpuri (flagship) grows ~30% YoY and is 'still growing', per Dr. Khanna. But Q1 overall growth was 9.1%, implying older hubs are flat/negative or new cohort ramping slowly. New hub unit economics (30 cycles/year Tier 2 = ~₹60 lakhs/year revenue post-break-even) may not sustain 30% FY target.
Management
Score 6/10. Dr. Khanna is articulate and market-aware, citing 27.5M infertile couples and 3L annual IVF cycles. Transparent on challenges (ART Act nascent, competition rising). However, defensiveness on Q1 weak growth and reliance on 'one-off' margin narrative suggest limited comfort defending shortfall. Track record mixed. FY26 46% growth, FY25 48%, Q1 FY27 9.1%—declining trend. One new hub live (South Extension) as of call date; 2 more in pipeline. Capex plan detailed and on track. But new-market hub execution unproven.
1 · Q2 FY27 (Sep 2026)
Gurgaon hub opens; revenue ramp-up post expansion push expected
2 · Q3 FY27 (Dec 2026)
Nagpur hub operational; 5 more hubs in execution for full ₹25 Cr capex
3 · FY28 (Apr 2027)
Lucknow women's hospital board-approved; initial construction phase begins
Short-term recovery from Q1 miss is uncertain; long-term structural case is solid but not yet reflected in current delivery.